Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (Nasdaq: ATRC) is a medical device company focused on surgical treatments and technologies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The ATRC news page on Stock Titan aggregates company announcements, clinical milestones, product updates, and financial disclosures that shape the outlook for this Afib and surgical pain management specialist.
Investors and healthcare professionals following AtriCure can use this feed to monitor earnings releases and financial guidance, which the company regularly reports via Form 8-K and press releases. Recent updates have included preliminary quarterly and full-year revenue results, non-GAAP metrics such as adjusted EBITDA and adjusted loss per share, and commentary on revenue growth across open ablation, minimally invasive ablation, pain management, and appendage management product categories in the United States and international markets.
The news stream also highlights product and technology developments. Examples include the launch of the cryoXT ae device for post-operative pain management following amputation, expansion of the cryoICE ae platform, and first-in-human use of a dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) using the EnCompass ae clamp. These announcements provide insight into AtriCure’s product pipeline and its efforts to enhance surgical ablation efficiency and pain control.
Another key theme in AtriCure’s news is clinical research and trials. Updates on the LeAAPS trial and the BoxX-NoAF trial illustrate the company’s focus on generating evidence for Afib treatment, LAA exclusion, and reduction of new-onset post-operative Afib. In addition, AtriCure frequently announces participation in major healthcare and investor conferences, offering context on how management communicates its strategy and performance to the market.
By reviewing ATRC news on this page, readers can quickly see the latest disclosures on financial performance, regulatory and clinical milestones, and device launches that may influence perceptions of AtriCure’s business and its role in Afib and surgical pain management.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in two investor conferences. The management team will present at the Stifel Healthcare Conference on November 18, 2020, at 11:20 a.m. ET, with a live webcast available on their website. Additionally, they will engage in one-on-one meetings at the Canaccord MedTech and Diagnostics Forum on November 19, 2020, without a webcast. AtriCure’s innovations are crucial in managing Afib, impacting over 33 million people globally and showcasing their FDA-approved Isolator® Synergy™ Ablation System.
AtriCure, a leader in treatments for atrial fibrillation (Afib), announced that it will release its third quarter 2020 financial results on November 5, 2020. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time on the same day. AtriCure's innovative technologies, like the FDA-approved Isolator® Synergy™ Ablation System and the AtriClip® Left Atrial Appendage Exclusion System, are widely utilized by medical professionals for Afib management, affecting over 33 million people globally. For further details, visit AtriCure.com.